ICPT - Canaccord cuts Intercept to hold calls Alfasigma deal best possible outcome
2023-09-26 18:57:20 ET
More on Intercept Pharma
- Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties
- Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade)
- Intercept Pharma unlikely to see rival offers, other roadblocks, analysts say
- Intercept surges after agreeing to $19/share offer from Alfasigma
- Drugmakers still chasing potentially lucrative NASH market, despite setbacks
For further details see:
Canaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"